Clinical Trials Logo

Intracranial Neoplasms clinical trials

View clinical trials related to Intracranial Neoplasms.

Filter by:
  • None
  • Page 1

NCT ID: NCT02563288 Recruiting - Clinical trials for Intracranial Aneurysm

Esmolol Versus Dexmedetomidine During Intracranial Procedures

Start date: August 2016
Phase: Phase 3
Study type: Interventional

Patients undergoing intracranial procedures may experience severe hypertension and tachycardia due to intracranial hypertension and to increased release of adrenaline. Preventing perioperative sympathetic activity is of great importance. A common technique is using b-blockers like esmolol, which effectively block perioperative hemodynamic changes during intracranial surgery. A2 agonists, like Dexmedetomidine-Dex are now being used as a component of a balanced anesthesia during neurosurgical procedures. This study aimed to evaluate whether esmolol or dex attenuates perioperative changes in patients undergoing elective craniotomy with fast track neuroanesthesia.

NCT ID: NCT02478346 Recruiting - Clinical trials for Cerebrovascular Disorders

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

Fluoescein
Start date: May 2015
Phase: Phase 4
Study type: Interventional

This study focuses on implementing Yellow 560 for the direct intraoperative visualization of Fluorescein Sodium stained intracranial lesions to facilitate extend of surgery, develop better treatment protocols, and improve the prognosis of a wide array of neurosurgical diseases. More specifically, for the patients who are undergoing surgical intervention for the treatment of their brain aneurysm, tumor, arteriovenous malformation or fistula, the investigators will inject the dye intraoperatively to assess for residual aneurysm, tumor or in general residual lesion which must be corrected.

NCT ID: NCT01445691 Not yet recruiting - Glioblastoma Clinical Trials

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to: - Make sure that 5-ALA helps the doctor remove more of the tumor. - Make sure 5-ALA does not cause any side effects. If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.

NCT ID: NCT00247403 Withdrawn - Neoplasm Metastasis Clinical Trials

Safety Study of 2DG With Stereotactic Radiosurgery

Start date: October 2005
Phase: Phase 1
Study type: Interventional

Ionizing radiation produces cancer cell death by creating high levels of reactive oxygen species (ROS), such as superoxide and hydrogen peroxide, in irradiated cells. Cancer cells are preferentially affected by ROS. The investigators, therefore, propose that interfering with the detoxification of ROS will make radiation more toxic to cancer cells. Several cellular mechanisms exist to detoxify ROS, and glucose metabolism plays an important role in many of these mechanisms. The investigators propose that interfering with glucose metabolism will sensitize cancer cells to radiation. The investigators' central hypothesis is that 2DG will sensitize cancer cells to ionizing radiation by inhibiting the use of glucose to detoxify reactive oxygen species produced by radiation. As an initial step to evaluate this hypothesis, the investigators have designed this phase I study.